Perceptions of Leadership in Quality Culture for Infection Prevention Among Intensive Care Nurses and Unit-Based Assessment of Antimicrobial Resistance Indicators in Intensive Care Units
This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Healthcare-associated infections (HAIs) remain a major global patient safety problem and are associated with prolonged hospital stays, increased healthcare costs, and higher mortality. The increasing prevalence of antimicrobial resistance (AMR) further complicates infection prevention and patient care.
Intensive care units are particularly vulnerable to healthcare-associated infections and antimicrobial resistance because of the high frequency of invasive procedures, the vulnerability of critically ill patients, and the extensive use of broad-spectrum antibiotics. Nurses play a central role in infection prevention and antimicrobial stewardship because they are continuously involved in patient care. However, previous studies have reported a gap between nurses' knowledge of infection prevention and adherence to recommended practices in clinical settings. Organizational culture and leadership may contribute to this gap.
Most previous studies have focused on healthcare professionals' self-reported perceptions of infection prevention. However, limited evidence is available regarding the relationship between nurses' perceptions of leadership and quality culture and objective antimicrobial resistance indicators at the intensive care unit level. Therefore, this study will assess nurses' perceptions using the Leadership in Quality Culture for Infection Prevention (LCQ-IP) instrument and examine their relationship with retrospective microbiological data from the participating intensive care units, including antimicrobial resistance rates and resistance profiles. The findings may provide evidence on the role of organizational leadership and quality culture in infection prevention and antimicrobial resistance management in intensive care settings.
Panoramica dello studio
Stato
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Yeliz Alakan, PhD lecturer
- Numero di telefono: 90 505 850 0222
- Email: yelizsapulu@uludag.edu.tr
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Nurses who have been actively working in an intensive care unit for at least 1 year.
- Nurses who voluntarily agree to participate in the study.
Exclusion Criteria:
- Student nurses or nursing interns.
- Nurses working temporarily or on a rotational basis in the intensive care unit.
- Nurses who have been actively working in an intensive care unit for at least 1 year.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Bursa
Intensive Care Nurses and Intensive Care Units in Bursa
|
|
Iğdır
Intensive Care Nurses and Intensive Care Units in Iğdır
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Leadership in Quality Culture for Infection Prevention (LCQ-IP) score among intensive care nurses
Lasso di tempo: Baseline
|
Leadership for a culture of quality in infection prevention will be assessed using the Turkish version of the Leading a Culture of Quality for Infection Prevention Scale.
The scale consists of 16 items rated on a 5-point Likert scale.
Total scores range from 16 to 80, with higher scores indicating a more positive perception of leadership for a culture of quality in infection prevention.
|
Baseline
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Antimicrobial Susceptibility Profiles of Bacterial Isolates from Intensive Care Units
Lasso di tempo: The 1-year period preceding study enrollment
|
The 1-year period preceding study enrollment
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Quality Culture (LCQ-IP)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .